Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories.
暂无分享,去创建一个
[1] C. Sutton,et al. Accurate assessment of adherence: self-report and clinician report vs electronic monitoring of nebulizers. , 2011, Chest.
[2] J Urquhart,et al. Effects on blood pressure and cardiovascular risk of variations in patients’ adherence to prescribed antihypertensive drugs: role of duration of drug action , 2011, International journal of clinical practice.
[3] P. Weiden,et al. Measurement of psychiatric treatment adherence. , 2010, Journal of psychosomatic research.
[4] I. Wilson. Adherence, Placebo Effects, and Mortality , 2010, Journal of general internal medicine.
[5] J. Urquhart,et al. Understanding Forgiveness: Minding and Mining the Gaps Between Pharmacokinetics and Therapeutics , 2010, Clinical pharmacology and therapeutics.
[6] Els Goetghebeur,et al. A structural mean model to allow for noncompliance in a randomized trial comparing 2 active treatments , 2010, Biostatistics.
[7] D. Marin,et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Steven Pearson,et al. Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers , 2010, Nature Reviews Drug Discovery.
[9] C. Vogeli,et al. Primary Medication Non-Adherence: Analysis of 195,930 Electronic Prescriptions , 2010, Journal of General Internal Medicine.
[10] L. Osterberg,et al. Electronic monitoring of patient adherence to oral antihypertensive medical treatment: a systematic review , 2009, Journal of hypertension.
[11] D. Morrow,et al. Factors Associated With Exacerbation of Heart Failure Include Treatment Adherence and Health Literacy Skills , 2009, Clinical pharmacology and therapeutics.
[12] J. Trussell. Understanding contraceptive failure. , 2009, Best practice & research. Clinical obstetrics & gynaecology.
[13] T. Nevins,et al. Quantitative Patterns of Azathioprine Adherence After Renal Transplantation , 2009, Transplantation.
[14] R. Altman,et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. , 2009, The New England journal of medicine.
[15] B. Vrijens,et al. “White Coat Compliance” Limits the Reliability of Therapeutic Drug Monitoring in HIV-1—Infected Patients , 2008, HIV clinical trials.
[16] D. Goff,et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. , 2008, Circulation.
[17] B. Vrijens,et al. Decreased adherence to antiretroviral therapy observed prior to transient human immunodeficiency virus type 1 viremia. , 2007, The Journal of infectious diseases.
[18] J. Cramer,et al. Methods for integrating medication compliance and persistence in pharmacoeconomic evaluations. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[19] Wanzhu Tu,et al. Pharmacist Intervention to Improve Medication Adherence in Heart Failure , 2007, Annals of Internal Medicine.
[20] J. Urquhart,et al. Estimation of the comparative therapeutic superiority of QD and BID dosing regimens, based on integrated analysis of dosing history data and pharmacokinetics , 2007, Journal of Pharmacokinetics and Pharmacodynamics.
[21] Honghu Liu. Repeated Measures Longitudinal Analyses of HIV Virologic Response as a Function of Percent Adherence, Dose Timing, Genotypic Sensitivity, and Other Factors , 2006, Journal of acquired immune deficiency syndromes.
[22] E. Lesaffre,et al. Effect of intervention through a pharmaceutical care program on patient adherence with prescribed once‐daily atorvastatin , 2006, Pharmacoepidemiology and drug safety.
[23] Els Goetghebeur,et al. Modelling the association between adherence and viral load in HIV‐infected patients , 2005, Statistics in medicine.
[24] L. Osterberg,et al. Adherence to medication. , 2005, The New England journal of medicine.
[25] K. Charalabopoulos,et al. Withdrawal syndrome following cessation of antihypertensive drug therapy , 2005, International journal of clinical practice.
[26] John Urquhart,et al. Successful Projection of the Time Course of Drug Concentration in Plasma During a 1‐Year Period From Electronically Compiled Dosing‐Time Data Used as Input to Individually Parameterized Pharmacokinetic Models , 2005, Journal of clinical pharmacology.
[27] Jingwei Wu,et al. Association Between Adherence Measurements of Metoprolol and Health Care Utilization in Older Patients with Heart Failure , 2005, Clinical pharmacology and therapeutics.
[28] E. Goetghebeur,et al. Structural Mean Effects of Noncompliance , 2004 .
[29] G. D. Johnston,et al. Comparison of the effects of a 7-day period of non-compliance on blood pressure control using three different antihypertensive agents , 2004, Journal of hypertension.
[30] D. Bangsberg,et al. Modeling the HIV protease inhibitor adherence-resistance curve by use of empirically derived estimates. , 2004, The Journal of infectious diseases.
[31] A. Struthers,et al. Furosemide responsiveness, non-adherence and resistance during the chronic treatment of heart failure: a longitudinal study. , 2004, British journal of clinical pharmacology.
[32] Els Goetghebeur,et al. Electronic monitoring of variation in drug intakes can reduce bias and improve precision in pharmacokinetic/pharmacodynamic population studies , 2004, Statistics in medicine.
[33] Richard I. Goldberg,et al. Acute myocardial infarction as a complication of clonidine withdrawal. , 2003, The Journal of emergency medicine.
[34] A. Hoes,et al. Effect of a pharmacist-led intervention on diuretic compliance in heart failure patients: a randomized controlled study. , 2003, Journal of cardiac failure.
[35] M. Burnier,et al. Monitoring compliance in resistant hypertension: an important step in patient management. , 2003, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.
[36] A. Hoes,et al. Patterns of pharmacotherapy in patients hospitalised for congestive heart failure , 2003, European journal of heart failure.
[37] Jerry Avorn,et al. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] J. Urquhart. History-Informed Perspectives on the Modeling and Simulation of Therapeutic Drug Actions , 2002 .
[39] Carl Peck,et al. Postmarketing drug dosage changes of 499 FDA‐approved new molecular entities, 1980–1999 , 2002, Pharmacoepidemiology and drug safety.
[40] John Urquhart,et al. Changes in prescribed drug doses after market introduction , 2002, Pharmacoepidemiology and drug safety.
[41] F. Dobbels,et al. Profiles of Patients Who Experienced a Late Acute Rejection Due to Nonadherence with Immunosuppressive Therapy , 2001, The Journal of cardiovascular nursing.
[42] A. Zolopa,et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. , 2001, AIDS.
[43] S. Tsutsui. A Double-Blind Comparative Study of Zolpidem versus Zopiclone in the Treatment of Chronic Primary Insomnia , 2001, The Journal of international medical research.
[44] M. Burnier,et al. Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions , 2001, Journal of hypertension.
[45] B. Prichard,et al. I1 imidazoline agonists. General clinical pharmacology of imidazoline receptors: implications for the treatment of the elderly. , 2000, Drugs & aging.
[46] Susan Swindells,et al. Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection , 2000, Annals of Internal Medicine.
[47] John Urquhart,et al. Pharmacoeconomic Consequences of Variable Patient Compliance With Prescribed Drug Regimens , 1999, PharmacoEconomics.
[48] Urquhart. Pharmacodynamics of variable patient compliance: implications for pharmaceutical value. , 1998, Advanced drug delivery reviews.
[49] P. Moons,et al. Late acute rejection and subclinical noncompliance with cyclosporine therapy in heart transplant recipients. , 1998, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[50] M. Fava,et al. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial , 1998, Biological Psychiatry.
[51] E. Garland,et al. Reviews : Pharmacotherapy of adolescent attention deficit hyperactivity disorder: challenges, choices and caveats , 1998, Journal of psychopharmacology.
[52] J Urquhart,et al. Contending paradigms for the interpretation of data on patient compliance with therapeutic drug regimens. , 1998, Statistics in medicine.
[53] B Vrijens,et al. Comparing compliance patterns between randomized treatments. , 1997, Controlled clinical trials.
[54] L B Sheiner,et al. Learning versus confirming in clinical drug development , 1997, Clinical pharmacology and therapeutics.
[55] T F Blaschke,et al. Patient compliance and drug failure in protease inhibitor monotherapy. , 1996, JAMA.
[56] C. Rand,et al. Noncompliance and treatment failure in children with asthma. , 1996, The Journal of allergy and clinical immunology.
[57] R. Carney,et al. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. , 1995, The New England journal of medicine.
[58] C Desforges,et al. Dose Frequency and Dose Interval Compliance with Multiple Antiepileptic Medications During a Controlled Clinical Trial , 1995, Epilepsia.
[59] D. Rubin,et al. Intention‐to‐treat analysis and the goals of clinical trials , 1995, Clinical pharmacology and therapeutics.
[60] Brian F. Johnson,et al. A STUDY DESIGN FOR COMPARING THE EFFECTS OF MISSING DAILY DOSES OF ANTIHYPERTENSIVE DRUGS , 1994, American journal of therapeutics.
[61] S. Weis,et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. , 1994, The New England journal of medicine.
[62] K. Calzone,et al. Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[63] Christopher J. L. Murray,et al. Tuberculosis: Commentary on a Reemergent Killer , 1992, Science.
[64] C. Cox,et al. Prediction of Diltiazem Plasma Concentration Curves From Limited Measurements Using Compliance Data , 1992, Clinical pharmacokinetics.
[65] J. Cramer. Medication compliance in epilepsy. , 1991, Archives of internal medicine.
[66] A R Feinstein,et al. On white-coat effects and the electronic monitoring of compliance. , 1990, Archives of internal medicine.
[67] J. Cramer,et al. Compliance declines between clinic visits. , 1990, Archives of internal medicine.
[68] J. Cramer,et al. How often is medication taken as prescribed? A novel assessment technique. , 1989, JAMA.
[69] J. Huttunen,et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. , 1988, JAMA.
[70] M. Houston,et al. Beta-adrenergic blocker withdrawal syndromes in hypertension and other cardiovascular diseases. , 1988, American heart journal.
[71] M. Kass,et al. A miniature compliance monitor for eyedrop medication. , 1984, Archives of ophthalmology.
[72] S. Langlois,et al. Comparison of withdrawal phenomena after propranolol, metoprolol and pindolol. , 1982, British journal of clinical pharmacology.
[73] J. Stewart,et al. Cardiac hyper‐ and hyporesponsiveness after pindolol withdrawal , 1982, Clinical pharmacology and therapeutics.
[74] S. Langlois,et al. Metoprolol withdrawal phenomena: Mechanism and prevention , 1982, Clinical pharmacology and therapeutics.
[75] M. Houston. Abrupt Discontinuation of Antihypertensive Therapy , 1981, Southern medical journal.
[76] D. Sackett,et al. Can Simple Clinical Measurements Detect Patient Noncompliance? , 1980, Hypertension.
[77] T. Blaschke,et al. Studies on the clinical pharmacology of prazosin. I: Cardiovascular, catecholamine and endocrine changes following a single dose. , 1980, British journal of clinical pharmacology.
[78] H. F. Wood,et al. RHEUMATIC FEVER IN CHILDREN AND ADOLESCENTS. A LONG-TERM EPIDEMIOLOGIC STUDY OF SUBSEQUENT PROPHYLAXIS, STREPTOCOCCAL INFECTIONS, AND CLINICAL SEQUELAE. I. DESCRIPTION OF THE INVESTIGATIVE TECHNIQUES AND OF THE POPULATION STUDIED. , 1964, Annals of internal medicine.
[79] M Christopher Roebuck,et al. Medication adherence leads to lower health care use and costs despite increased drug spending. , 2011, Health affairs.
[80] S. Cosgrove,et al. Antimicrobial stewardship. , 2011, Infectious disease clinics of North America.
[81] T. Gilmer,et al. Evaluation of the First Year of a Pilot Program in Community Pharmacy: HIV/AIDS Medication Therapy Management for Medi-Cal Beneficiaries , 2009, Journal of managed care pharmacy : JMCP.
[82] W. J. Elliott,et al. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories , 2009 .
[83] R B Haynes,et al. Interventions for enhancing medication adherence. , 2008, The Cochrane database of systematic reviews.
[84] Haynes Rb,et al. Interventions for enhancing medication adherence (Review) , 2008 .
[85] Yingying Ma,et al. How well do clinicians estimate patients’ adherence to combination antiretroviral therapy? , 2007, Journal of General Internal Medicine.
[86] G. Chouinard,et al. Persistent tardive rebound panic disorder, rebound anxiety and insomnia following paroxetine withdrawal: a review of rebound-withdrawal phenomena. , 2006, The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique.
[87] J. Urquhart. How Much Compliance Is Enough? , 2004, Pharmaceutical Research.
[88] Jeffrey S. Barrett,et al. Pharmacokinetic/Pharmacodynamic Modeling in Drug Development , 2004 .
[89] T F Blaschke,et al. Medication compliance as a feature in drug development. , 1997, Annual review of pharmacology and toxicology.
[90] S T Cole,et al. Mechanisms of drug resistance in Mycobacterium tuberculosis. , 1996, Current topics in microbiology and immunology.
[91] P. Meredith,et al. Concentration-effect analysis of antihypertensive drug response. Focus on calcium antagonists. , 1994, Clinical pharmacokinetics.
[92] C. Peck,et al. Chronobiology. Suggestions for integrating it into drug development. , 1991, Annals of the New York Academy of Sciences.
[93] Ling-Fu Meng,et al. Patient Compliance in Medical Practice and Clinical Trials , 1991 .
[94] J. Guillebaud. The forgotten pill--and the paramount importance of the pill-free week. , 1987 .
[95] Malcolm Rowland,et al. Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications , 1980 .